Skip to main content

Advertisement

SpringerLink
Log in

Does treatment of lichen sclerosus improve overactive bladder symptoms?

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Lichen sclerosus (LS) is a chronic disease which mainly affects the vulvar area in women. A few studies have shown a possible relationship between LS and overactive bladder (OAB) symptoms, but no studies have investigated whether OAB symptoms improve after initiating treatment of LS. The aim of this study was to investigate whether the treatment of LS also improves OAB symptoms in women newly diagnosed with LS.

Methods

This was a prospective cohort pilot study based on questionnaires from women newly diagnosed with LS and with symptoms of OAB. Women above the age of 18 who were newly diagnosed with LS were included. The women completed two questionnaires on OAB at inclusion and after 3 months. The questionnaires consisted of the validated questionnaires OAB-q (33 questions, maximum score 198) and ICIQ-OAB (8 questions, maximum score 56). All women initiated treatment with local steroid by the time of the LS diagnosis.

Results

A total of 40 women were included, and 13 women dropped out during the data collection time. Comparing month 0 to month 3 for the remaining 27 women, a mean difference at 28.8 points was observed for OAB-q and a mean difference of 5.7 points was observed for ICIQ-OAB. Both results showed a statistically significant difference after 3 months (p < 0.05). A total of 92.6% (25/27) of the women improved their symptoms.

Conclusion

Treatment with local steroid might improve OAB symptoms in women newly diagnosed with LS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Swenson C, Menees S, Haefner H, Berger M. Lower urinary tract and functional bowel symptoms in women with vulvar diseases and controls. Female Pelvic Med Reconstr Surg. 2015;21(4):211–4.

    Article  PubMed  PubMed Central  Google Scholar 

  2. McPherson T, Cooper S. Vulval lichen sclerosus and lichen planus. Dermatol Ther. 2010;523

  3. Christmann-Schmid C, Hediger M, Gröger S, Krebs J, Günthert AR. Vulvar lichen sclerosus in women is associated with lower urinary tract symptoms. Int Urogynecol J. 2017:217–21.

  4. Powell JJ, Wojnarowska F. Lichen sclerosus. The Lancet. 1999;353:1777–83.

    Article  CAS  Google Scholar 

  5. Günthert AR, Faber M, Knappe G, Hellriegel S, Emons G. Early onset vulvar lichen sclerosus in premenopausal women and oral contraceptives. Eur J Obstetrics Gynecol Reprod Biol. 2007:56–60.

  6. Eana D, Unaro F. Lichen sclerosus: a review and practical approach. Dermatologic Therapy. 2004;17:28–37.

    Article  Google Scholar 

  7. Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, et al. New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases. J Eur Acad Dermatol Venereol. 2016;31(4):699.

    Article  PubMed  Google Scholar 

  8. Pérez-López FR, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Rees M, et al. EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. Maturitas. 2013;74(3):279–82.

    Article  PubMed  Google Scholar 

  9. Neill SM, Lewis FM, Tatnall FM, Cox NH. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol (1951). 2010;163(4):672–82.

  10. Regauer S. Immune dysregulation in lichen sclerosus. Eur J Cell Biol. 2005;274.

  11. Kolitz E, Gammon L, Mauskar M. Vulvar lichen sclerosus in women of reproductive age. Baylor Univ Med Center Proc. 2021:349–51.

  12. Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020:1–8.

  13. Kazandi M, Sahim C, Terek MC, Cirpan T, Oztekin K. Clinical evaluation of vulvar lichen sclerosus. Case series, European journal of Gynaecological Oncology. 2010;31:483–597, 555–8.

  14. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus. Am J Clin Dermatol. 2012;29

  15. Meyrick Thomas RH, Ridley CM, Mcgibbon DH, Black MM. Lichen sclerosus et atrophicus and autoimmunity - a study of 350 women. British Journal of Dermatology 1987:41–46.

  16. Hagedorn M, Buxmeyer B, Schmitt Y, Bauknecht T. Survey of genital lichen sclerosus in women and men. Arch Gyncol Obstet. 2001:86–91

  17. Debra L, Birenbaum MD, Roger C, Young MD. High prevalence of thyroid disease in patients with lichen sclerosus. Journal of Reproductive Medicine. 2007;52(1):28–30.

    Google Scholar 

  18. Cooper SM, Ali I, Baldo M, Wojnarowska F. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: A case-control study. Arch Dermatol (1960) 2008;144(11):1432–5.

  19. Kreuter A, Kryvosheyeva Y, Terras S, Moritz R, Möllenhoff K, Altmeyer P, et al. Association of autoimmune diseases with lichen sclerosus in 532 male and female patients. Acta Derm Venereol. 2013;93(2):238–41.

  20. Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol (1951). 2014;171(2):388–96.

  21. Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol (1951). 2013;168(6):1316–24.

  22. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Therapy. 2005;22(4):381–94.

    Article  Google Scholar 

  23. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res. 2002;34(6):563–74.

    Article  Google Scholar 

  24. International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB). Available at: https://iciq.net/iciq-oab. Accessed Dec 2021.

  25. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3):197–207.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Higgins CA, Cruickshank ME. A population-based case-control study of aetiological factors associated with vulval lichen sclerosus. J Obstet Gynaecol. 2012;32(3):271–5.

    Article  CAS  PubMed  Google Scholar 

  27. Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. Prospective clinical and epidemiologic study of vulvar lichen sclerosus: Analysis of prevalence and severity of clinical features, together with historical and demographic associations. Dermatology (Basel). 2014;149.

Download references

Author information

Authors and Affiliations

  1. Aalborg University, Aalborg, Denmark

    Sofie Balling Olsen

  2. Department of Gynaecology and Obstetrics, Aalborg University Hospital, Aalborg, Denmark

    Helle Odgaard & Karin Glavind

Authors
  1. Sofie Balling Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helle Odgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Glavind
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.B. Olsen: Data collection and management, Data analysis, Manuscript writing.

H. Odgaard: Data collection, Project development, Protocol development.

K. Glavind: Data collection, Project development, Protocol development, Manuscript editing.

Corresponding author

Correspondence to Karin Glavind.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olsen, S.B., Odgaard, H. & Glavind, K. Does treatment of lichen sclerosus improve overactive bladder symptoms?. Int Urogynecol J 34, 1203–1209 (2023). https://doi.org/10.1007/s00192-022-05318-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-022-05318-y

Keywords

Search

Navigation